OTCMKTS:NEVPF

Abliva AB (publ) Stock Forecast, Price & News

$0.11

0.00 (-0.92 %)

(As of 07/30/2021 09:47 AM ET)

Add

Compare

Today's Range

$0.11

▼

$0.11

50-Day Range

$0.06

▼

$0.12

52-Week Range

$0.06

▼

$0.13

Volume100 shs

Average Volume7,022 shs

Market Capitalization$29.04 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive NEVPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

About Abliva AB (publ)

Abliva AB engages in the research and development of pharmaceuticals that protect mitochondria from death post acute traumatic injury. Its projects include KL1333 AND NV354. The company was founded by Eskil Elmer on February 1, 2000 and is headquartered in Lund, Sweden.

Abliva AB (publ) (OTCMKTS:NEVPF) Short Interest Update
July 30, 2021 | americanbankingnews.com

Abliva AB (publ) (OTCMKTS:NEVPF) Short Interest Up 107.1% in June
July 15, 2021 | americanbankingnews.com

BioInvent strengthens Investor Relations
November 28, 2020 | finanznachrichten.de

Venture Fund Manager Has $100 Million for Startups Run by Women
June 28, 2020 | finance.yahoo.com

Here's Why NeuroVive Pharmaceutical (STO:NVP) Must Use Its Cash Wisely
April 7, 2020 | finance.yahoo.com

NeuroVive Pharmaceutical AB reports Q4 results
February 19, 2020 | seekingalpha.com

Investors Who Bought NeuroVive Pharmaceutical (STO:NVP) Shares Five Years Ago Are Now Down 98%
February 4, 2020 | finance.yahoo.com

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
December 20, 2019 | markets.businessinsider.com

NeuroVive settles dispute with CicloMulsion AG
December 16, 2019 | seekingalpha.com

NeuroVive Announces Settlement in Dispute With CicloMulsion AG
December 16, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NEVPF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.neurovive.com
Phone(646) 275-6220
Employees7
Year FoundedN/A

Sales & Book Value

Annual Sales$20,000.00
Price / Sales1,452.19
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.06 per share
Price / Book1.80

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares269,673,000
Market Cap$29.04 million
Next Earnings Date8/20/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.88 out of 5 stars

Medical Sector

1729th out of 2,221 stocks

Pharmaceutical Preparations Industry

742nd out of 869 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Abliva AB (publ).

4.4 Community Rank

Outperform Votes
Abliva AB (publ) has received 70 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Abliva AB (publ) has received 35 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Abliva AB (publ) has received 66.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Abliva AB (publ) and other stocks. Vote “Outperform” if you believe NEVPF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEVPF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Abliva AB (publ) does not currently pay a dividend.
Dividend Growth
Abliva AB (publ) does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Abliva AB (publ) insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Abliva AB (publ) is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Abliva AB (publ) is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Abliva AB (publ) has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Abliva AB (publ) (OTCMKTS:NEVPF) Frequently Asked Questions

What stocks does MarketBeat like better than Abliva AB (publ)?

Wall Street analysts have given Abliva AB (publ) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abliva AB (publ) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Abliva AB (publ)?

Abliva AB (publ) saw a drop in short interest in July. As of July 15th, there was short interest totaling 10,300 shares, a drop of 40.8% from the June 30th total of 17,400 shares. Based on an average trading volume of 9,300 shares, the short-interest ratio is presently 1.1 days.
View Abliva AB (publ)'s Short Interest.

When is Abliva AB (publ)'s next earnings date?

Abliva AB (publ) is scheduled to release its next quarterly earnings announcement on Friday, August 20th 2021.
View our earnings forecast for Abliva AB (publ).

How has Abliva AB (publ)'s stock been impacted by Coronavirus?

Abliva AB (publ)'s stock was trading at $0.0796 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NEVPF shares have increased by 35.3% and is now trading at $0.1077.
View which stocks have been most impacted by COVID-19.

Who are Abliva AB (publ)'s key executives?

Abliva AB (publ)'s management team includes the following people:

Ellen k. Donnelly, Chief Executive Officer
Catharina Jz Johansson, Chief Financial Officer & VP-Communications
Eskil Elmér, Chief Scientific Officer & Manager-Research
Magnus Hansson, Chief Medical Officer & VP-Preclinical Development
Mark Farmery, Vice President-Business Development

Who are some of Abliva AB (publ)'s key competitors?

Some companies that are related to Abliva AB (publ) include Kazia Therapeutics (KZIA), POINT Biopharma Global (PNT), InflaRx (IFRX), Galecto (GLTO), ASLAN Pharmaceuticals (ASLN), LifeVantage (LFVN), Cocrystal Pharma (COCP), Agile Therapeutics (AGRX), Eyenovia (EYEN), Biophytis (BPTS), ProPhase Labs (PRPH), F-star Therapeutics (FSTX), Longeveron (LGVN), Concert Pharmaceuticals (CNCE) and Vascular Biogenics (VBLT).
View all of NEVPF's competitors.

What is Abliva AB (publ)'s stock symbol?

Abliva AB (publ) trades on the OTCMKTS under the ticker symbol "NEVPF."

How do I buy shares of Abliva AB (publ)?

Shares of NEVPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abliva AB (publ)'s stock price today?

One share of NEVPF stock can currently be purchased for approximately $0.11.

How much money does Abliva AB (publ) make?

Abliva AB (publ) has a market capitalization of $29.04 million and generates $20,000.00 in revenue each year.

How many employees does Abliva AB (publ) have?

Abliva AB (publ) employs 7 workers across the globe.

What is Abliva AB (publ)'s official website?

The official website for Abliva AB (publ) is www.neurovive.com.

Where are Abliva AB (publ)'s headquarters?

Abliva AB (publ) is headquartered at MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381.

How can I contact Abliva AB (publ)?

Abliva AB (publ)'s mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381. The company can be reached via phone at (646) 275-6220 or via email at [email protected]

This page was last updated on 8/2/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Abliva AB (publ) Stock Forecast, Price & News

About Abliva AB (publ)

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

4.4 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

Dividend Yield

Dividend Growth